<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39313792</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Utilization frequency and patient-reported effectiveness of symptomatic therapies in post-COVID syndrome.</ArticleTitle><Pagination><StartPage>2577</StartPage><MedlinePgn>2577</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2577</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-024-19951-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To date there is no causal treatment for post-COVID syndrome, leaving symptomatic treatments as the primary recourse. However, the practical implementation and effectiveness of these interventions remain underexplored. This study aimed to investigate the utilization frequency of symptomatic therapies and patient-reported effectiveness across various treatment modalities at a German post-COVID center.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">As the baseline investigation we conducted a single-cohort retrospective study to analyze the frequency of symptomatic therapies among post-COVID patients who attended the post-COVID center of the University Hospital of Erlangen, between December 2022 to July 2023. Additionally, we administered a follow-up at least 3 months after the initial presentation, using a questionnaire to assess patient-reported improvements in post-COVID symptoms associated with the symptomatic therapies received.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our study included 200 patients (mean age: 44.6 ± 12.6 years; 69.0% women; mean duration since acute infection: 15.3 ± 8.3 months). Pharmacotherapy was the predominant symptomatic treatment (79.5%), with psychotropic drugs (32.5%) and analgesics (31.5%) being the most frequently prescribed. Over half of the patients (55.5%) utilized vitamins and nutritional supplements. Hospital admission rates to acute care occurred in 35.5% of cases; 33.0% underwent inpatient rehabilitation and 31.0% pursued outpatient psychotherapy. Cardiologists (76.5%), pulmonologists (67.5%), and neurologists (65.5%) were the most consulted specialists. Therapies involving medical devices were infrequently employed (12.0%). In a follow-up questionnaire (response rate: 82.5%, 6.3 ± 2.2 months post-baseline), beta-blockers were the most effective pharmacological intervention with 31.5% of patients reporting strong to very strong symptom improvement, followed by antibiotics (29.6%). Furthermore, 33.0% of the patients perceived plasmapheresis to strongly alleviate symptoms. Only a small proportion of the sample attributed a strong or very strong symptom improvement to outpatient psychotherapy (11.0%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study provides initial insights into symptomatic therapy utilization and patient-reported symptom improvement in post-COVID syndrome. Further research into symptoms clusters and interdisciplinary collaboration are warranted to comprehensively address the multifaceted physical and psychological symptomatology.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The study was registered at the German Clinical Trials Register (DRKS-ID: DRKS00033621) on March 20, 2024.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reuner</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krehbiel</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Post-COVID Center, University Hospital of Erlangen, 91054, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rech</LastName><ForeName>Jürgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Post-COVID Center, University Hospital of Erlangen, 91054, Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine III, Rheumatology and Immunology, University Hospital of Erlangen, Friedrich- Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greiner</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schäfer</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herold</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Morawa</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany. eva.morawa@uk-erlangen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Erim</LastName><ForeName>Yesim</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Post-COVID Center, University Hospital of Erlangen, 91054, Erlangen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="Y">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Effectiveness</Keyword><Keyword MajorTopicYN="N">Medication</Keyword><Keyword MajorTopicYN="N">Post-COVID-19</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>0</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39313792</ArticleId><ArticleId IdType="pmc">PMC11421202</ArticleId><ArticleId IdType="doi">10.1186/s12889-024-19951-3</ArticleId><ArticleId IdType="pii">10.1186/s12889-024-19951-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Number of COVID-19 cases reported to WHO (cumulative total) 2024. https://data.who.int/dashboards/covid19/cases?n=c. Accessed 21. March 2024.</Citation></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13(1):3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryuchkov I. Post COVID-19 condition (Long COVID): World Health Organization; 2022. https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition. Accessed 21. March 2024.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194–202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallek M, Adorjan K, Behrends U, Ertl G, Suttorp N, Lehmann C. Post-COVID syndrome. Dtsch Arztebl Int. 2023;120(4):48–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10060997</ArticleId><ArticleId IdType="pubmed">36633452</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafi MB, Javanmard SH. Post-COVID-19 syndrome mechanisms, prevention and management. Int J Prev Med. 2023;14:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10284243</ArticleId><ArticleId IdType="pubmed">37351054</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffke M, Freitag H, Rudolf G, Seifert M, Doehner W, Scherbakov N, et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med. 2022;20(1):138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938726</ArticleId><ArticleId IdType="pubmed">35317812</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S, Ibn Hadj Amor H, Jdidi J, Torjmen S, Kraiem S, Hammami R, et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction?  Insights from TUN-EndCOV study. Front Cardiovasc Med. 2021;8:745758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670225</ArticleId><ArticleId IdType="pubmed">34917659</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, de Maertens C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54(1):1473–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibenbogen C, Bellmann-Strobl JT, Heindrich C, Wittke K, Stein E, Franke C, et al. Fighting Post-COVID and ME/CFS - development of curative therapies. Front Med (Lausanne). 2023;10:1194754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10309204</ArticleId><ArticleId IdType="pubmed">37396922</ArticleId></ArticleIdList></Reference><Reference><Citation>Harandi AA, Pakdaman H, Medghalchi A, Kimia N, Kazemian A, Siavoshi F, et al. A randomized open-label clinical trial on the effect of amantadine on post covid 19 fatigue. Sci Rep. 2024;14(1):1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10792128</ArticleId><ArticleId IdType="pubmed">38228731</ArticleId></ArticleIdList></Reference><Reference><Citation>Rus CP, de Vries BEK, de Vries IEJ, Nutma I, Kooij JJS. Treatment of 95 post-covid patients with SSRIs. Sci Rep. 2023;13(1):18599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10622561</ArticleId><ArticleId IdType="pubmed">37919310</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi M, Saleh Y, Ahmed A, Benjanuwattra J, Leelaviwat N, Almaghraby A. Ivabradine effects on COVID-19-associated postural orthostatic tachycardia syndrome: a single center prospective study. Am J Cardiovasc Dis. 2023;13(3):162–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10352820</ArticleId><ArticleId IdType="pubmed">37469536</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoof A. Comparison of the effiacy of β blocker and ivabradine in Post COVID-19 associated inappropriate sinus tachycardia. J Cardiovasc Disease Res. 2022;13(04,2022):57–63.</Citation></Reference><Reference><Citation>di Filippo L, Frara S, Nannipieri F, Cotellessa A, Locatelli M, Rovere Querini P, Giustina A. Low vitamin D levels are Associated with Long COVID Syndrome in COVID-19 survivors. J Clin Endocrinol Metab. 2023;108(10):e1106–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10505553</ArticleId><ArticleId IdType="pubmed">37051747</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathi A, Jadhav SB, Shah N. A randomized controlled trial of the efficacy of systemic enzymes and probiotics in the resolution of Post-COVID fatigue. Med (Basel). 2021;8(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8472462</ArticleId><ArticleId IdType="pubmed">34564089</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu TH, Ho CH, Chen DT, Wu JY, Huang PY, Lai CC, et al. Omega-3 polyunsaturated fatty acids and the psychiatric post-acute sequelae of COVID-19: a one-year retrospective cohort analysis of 33,908 patients. Brain Behav Immun. 2023;114:453–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">37716377</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CP, Chang CM, Yang CC, Pariante CM, Su KP. Long COVID and long chain fatty acids (LCFAs): psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19. Brain Behav Immun. 2022;103:19–27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8977215</ArticleId><ArticleId IdType="pubmed">35390469</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollbracht C, Kraft K. Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients. 2021;13(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8066596</ArticleId><ArticleId IdType="pubmed">33807280</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo R, Trimarco V, Mone P, Aloè T, Capra Marzani M, Diana A, et al. Combining L-Arginine with vitamin C improves long-COVID symptoms: the LINCOLN Survey. Pharmacol Res. 2022;183:106360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9295384</ArticleId><ArticleId IdType="pubmed">35868478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen KS, Mogensen TH, Agergaard J, Schiøttz-Christensen B, Østergaard L, Vibholm LK, Leth S. High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trial. Lancet Reg Health Eur. 2023;24:100539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9627534</ArticleId><ArticleId IdType="pubmed">36337437</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Marques O, Halpert G, Schimke LF, Ostrinski Y, Vojdani A, Baiocchi GC, et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat Commun. 2022;13(1):1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8907309</ArticleId><ArticleId IdType="pubmed">35264564</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox T, Hunt BJ, Ariens RA, Towers GJ, Lever R, Garner P, Kuehn R. Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition. Cochrane Database Syst Rev. 2023;7(7):Cd015775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10368521</ArticleId><ArticleId IdType="pubmed">37491597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenmann J, Porubsky C, Okresa L, Klemen H, Mykoliuk I, Roj A et al. Immediate and Long-Term effects of hyperbaric oxygenation in patients with long COVID-19 syndrome using SF-36 Survey and VAS score: a clinical pilot study. J Clin Med. 2023;12(19).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10573231</ArticleId><ArticleId IdType="pubmed">37834897</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan JQ, Tian ZM, Xue LB. Hyperbaric oxygen treatment for long COVID: from molecular mechanism to clinical practice. Curr Med Sci. 2023;43(6):1061–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">37924387</ArticleId></ArticleIdList></Reference><Reference><Citation>Huth D, Bräscher AK, Tholl S, Fiess J, Birke G, Herrmann C, et al. Cognitive-behavioral therapy for patients with post-COVID-19 condition (CBT-PCC): a feasibility trial. Psychol Med. 2024;54(6):1122–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">37842765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuut TA, Müller F, Csorba I, Braamse A, Aldenkamp A, Appelman B, et al. Efficacy of cognitive-behavioral therapy targeting severe fatigue following Coronavirus Disease 2019: results of a Randomized Controlled Trial. Clin Infect Dis. 2023;77(5):687–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10495128</ArticleId><ArticleId IdType="pubmed">37155736</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawzy NA, Abou Shaar B, Taha RM, Arabi TZ, Sabbah BN, Alkodaymi MS, et al. A systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on WHO International clinical trials platform. Clin Microbiol Infect. 2023;29(5):570–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9837206</ArticleId><ArticleId IdType="pubmed">36642173</ArticleId></ArticleIdList></Reference><Reference><Citation>Fugazzaro S, Contri A, Esseroukh O, Kaleci S, Croci S, Massari M et al. Rehabilitation interventions for Post-acute COVID-19 syndrome: a systematic review. Int J Environ Res Public Health. 2022;19(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9104923</ArticleId><ArticleId IdType="pubmed">35564579</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai T, Hoshino C, Hirao M, Nakano M, Takashina Y, Okawa A. Rehabilitation of patients with Post-COVID-19 syndrome: a narrative review. Prog Rehabil Med. 2023;8:20230017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10261367</ArticleId><ArticleId IdType="pubmed">37323367</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M, et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20(11):102947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>AWMF online. S3-Leitlinie - Empfehlungen zur Therapie von Patienten mit COVID-19 2023. https://register.awmf.org/assets/guidelines/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2023-03.pdf. Accessed 21. March 2024.</Citation></Reference><Reference><Citation>Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen 2024. https://www.bfarm.de/SharedDocs/Downloads/DE/Kodiersysteme/ATC/atc-ddd-amtlich-2024.pdf?__blob=publicationFile. Accessed 21. March 2024.</Citation></Reference><Reference><Citation>Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. Washington (DC): National Academies Press (US); 2015. The National Academies Collection: Reports funded by National Institutes of Health.</Citation></Reference><Reference><Citation>Bygdell M, Leach S, Lundberg L, Gyll D, Martikainen J, Santosa A, et al. A comprehensive characterization of patients diagnosed with post-COVID-19 condition in Sweden 16 months after the introduction of the International classification of diseases Tenth Revision diagnosis code (U09.9): a population-based cohort study. Int J Infect Dis. 2023;126:104–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9678230</ArticleId><ArticleId IdType="pubmed">36410693</ArticleId></ArticleIdList></Reference><Reference><Citation>FAIR Health I. Patients diagnosed with post-COVID conditions: an analysis of private healthcare claims using the official ICD-10 diagnostic code FAIR Health white paper 2022.</Citation></Reference><Reference><Citation>Adorjan K. Post-COVIDLMU: implementation and evaluation of an interdisciplinary and cross-sectoral healthcare and research network for evidence-based treatment of patients with severe post-COVID syndrome. Nervenarzt. 2022;93(8):797–803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9190193</ArticleId><ArticleId IdType="pubmed">35695907</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Foer D, Zhang Y, Karlson EW, Bates DW, Zhou L, Post-Acute. COVID-19 respiratory symptoms in patients with asthma: an Electronic Health records-based study. J Allergy Clin Immunol Pract. 2023;11(3):825–e353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9773736</ArticleId><ArticleId IdType="pubmed">36566779</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Low PA, Opfer-Gehrking TL, Textor SC, Benarroch EE, Shen WK, Schondorf R, et al. Postural tachycardia syndrome (POTS). Neurology. 1995;45(4 Suppl 5):S19–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">7746369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormiston CK, Świątkiewicz I, Taub PR. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. Heart Rhythm. 2022;19(11):1880–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9287587</ArticleId><ArticleId IdType="pubmed">35853576</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch MA, Maske UE, Ryl L, Schlack R, Hapke U. [Prevalence of depressive symptoms and diagnosed depression among adults in Germany: results of the German health interview and examination survey for adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5–6):733–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23703492</ArticleId></ArticleIdList></Reference><Reference><Citation>Steppuhn H, Kuhnert R, Scheidt-Nave C. 12-month prevalence of asthma among adults in Germany. J Health Monit. 2017;2(3):34–42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10165913</ArticleId><ArticleId IdType="pubmed">37168951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunata K, Miyata J, Terai H, Matsuyama E, Watase M, Namkoong H et al. Asthma is a risk factor for general fatigue of long COVID in Japanese nation-wide cohort study. Allergol Int. 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">37996384</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, Palladini M, Villa G, De Lorenzo R, Rovere Querini P, Benedetti F. Prevalence, trajectory over time, and risk factor of post-COVID-19 fatigue. J Psychiatr Res. 2022;155:112–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9391361</ArticleId><ArticleId IdType="pubmed">36029623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Quan L, Chavarro JE, Slopen N, Kubzansky LD, Koenen KC, et al. Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post-COVID-19 conditions. JAMA Psychiatry. 2022;79(11):1081–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9453634</ArticleId><ArticleId IdType="pubmed">36069885</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczulla A. S1-Leitlinie Long/ Post-COVID: AWMF online; 2023. https://register.awmf.org/assets/guidelines/020-027l_S1_Long-Post-Covid_2023-11.pdf. Accessed 21. March 2024.</Citation></Reference><Reference><Citation>Schettler V. Apheresetherapie bei Patientinnen und Patienten mit Long-/Post-COVID-Syndrom (aktualisiert): Deutsche Gesellschaft für Nephrologie; 2022.https://www.dgfn.eu/stellungnahmen-details/apheresetherapie-long-post-covid-syndrom.html. Accessed 21. March 2024.</Citation></Reference><Reference><Citation>Al-Jabr H, Hawke LD, Thompson DR, Clifton A, Shenton M, Castle DJ, Ski CF. Interventions to support mental health in people with long COVID: a scoping review. BMC Public Health. 2023;23(1):1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10280822</ArticleId><ArticleId IdType="pubmed">37340400</ArticleId></ArticleIdList></Reference><Reference><Citation>Grande T, Grande B, Gerner P, Hammer S, Stingl M, Vink M, Hughes BM. The role of pychotherapy in the care of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Med (Kaunas). 2023;59(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10145115</ArticleId><ArticleId IdType="pubmed">37109676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmitt A, Jöbges M, Randerath J, Hinterberger T, Loew TH, Köllner V. Attention deficits and depressive symptoms improve differentially after rehabilitation of post-COVID condition - A prospective cohort study. J Psychosom Res. 2023;175:111540.</Citation><ArticleIdList><ArticleId IdType="pubmed">37918327</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Tallawy SN, Perglozzi JV, Ahmed RS, Kaki AM, Nagiub MS, LeQuang JK, Hadarah MM. Pain Management in the Post-COVID Era-An update: a narrative review. Pain Ther. 2023;12(2):423–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9971680</ArticleId><ArticleId IdType="pubmed">36853484</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87:104413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. 2022;32(4):e2315.</Citation><ArticleIdList><ArticleId IdType="pubmed">34888989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>